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Samantha M. Jaglowski,1 John C. Byrd1,2Over the past decade, numerous advances have been made in elucidating the biology of and improving treat-
ment for chronic lymphocytic leukemia (CLL). These studies have led to identification of select CLL patient
groups that generally have short survival dating from time of treatment or initial disease relapse who benefit
from more aggressive therapeutic interventions. Allogeneic transplantation represents the only potentially
curative option for CLL, but fully ablative regimens applied in the past have been associated with significant
morbidity andmortality. Reduced-intensity preparative regimens hasmade applicationof allogeneic transplant
to CLL patients muchmore feasible and increased the number of patients proceeding to this modality. Arising
from this has been establishment of guidelines where allogeneic stem cell transplantation should be consid-
ered in CLL. Introduction of new targeted therapies with less morbidity, which can produce durable remis-
sions has the potential to redefine where transplantation is initiated in CLL. This review briefly summarizes
the field of allogeneic stem cell transplant in CLL and the interface of new therapeutics with this modality.
Biol Blood Marrow Transplant 18: S132-S138 (2012)  2012 American Society for Blood and Marrow TransplantationINTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most
common leukemia diagnosed in Western countries,
with an incidence of about 2 to 6 cases per 100,000
people per year, increasing to a rate of 12.8 per
100,000 at age 65 [1,2]. CLL is characterized by an
accumulation of leukemic cells caused, in part,
because of survival signals delivered to the cells from
various receptors and ligands. Improvement in initial
therapies of CLL with chemoimmunotherapy in all
but high-risk genomic groups has led to high response
rates and longer remissions. Following relapse, remis-
sions following second-line therapy are often shorter.
CLL remains incurable outside the setting of alloge-
neic stem cell transplant, and therefore, identification
of the appropriate time for transitioning CLL patients1Department of Internal Medicine, Division of Hematol-
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6/j.bbmt.2011.11.018to transplant and having effective disease control at
that time represents a major issue. For patients with
high-risk disease, such as del(17p) or poor response
to initial therapy, the consensus of several groups is
that transition to allogeneic transplant early in the dis-
ease course is the best strategy. For those with durable
first remissions the timing of transplant is more con-
troversial. The controversy in when to proceed to
a more aggressive treatment approach is in part driven
by the plethora of new therapeutics available for CLL
patients. Indeed, commonalities in the pathways in the
development and expansion of mature B lymphocytes
to clonal CLL lymphocytes have been observed allow-
ing for the development of targeted therapies [2].
Efforts to target specific pathways in CLL have led
to the development of exciting novel therapeutics,
changing the way we approach patients with CLL. It
is not yet known how, if at all, these therapies will
change the indications for or outcomes following
transplant for CLL. However, these promising results
as documented herein already have started to impact
on transplantation recommendations for CLL patients
in a manner similar to chronic myeloid leukemia
(CML) patients in the early days of imatinib treatment,
where durable remissions were observed. At that time,
it was common for both patients and physicians to
struggle with the correct decision about continuing
therapy with imatinib or proceeding to transplant.
More than a decade later, with the long-term follow-
up of imatinib available as well as the development of
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cluding dasitinib and nilotinib, allogeneic transplant
is only considered for a very small subset of high-risk
CML patients. This paper provides a prospective of
where CLL is relative to this therapeutic balance of
new targeted agents, their integration into allogeneic
transplantation, and impact on choice of when to pro-
ceed with this curative but potentially more morbid
treatment.REDUCED-INTENSITY CONDITIONING (RIC)
HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) FOR CLL
Although myeloablative transplant in CLL can
result in durable remissions, rates of transplant-
related mortality (TRM) are unacceptably high, rang-
ing from 46% to 57% [3,4]. Patients who survive,
notably those who develop chronic graft-versus-host
disease (cGVHD), have a good chance of developing
long-term disease control, suggesting a strong graft-
versus-leukemia (GVL) effect in this disease. The
high mortality of myeloablative transplant in CLL
even among young patients greatly reduced its applica-
tion, even in the most refractory and high-risk individ-
uals. Reduced-intensity conditioning (RIC) regimens
were introduced as a way to exploit the GVL effect
while reducing TRM, making transplant more avail-
able to a patient population where the median age at
diagnosis is 72.
Fludarabine was evaluated by researchers at M.D.
Anderson as a conditioning agent for RIC HSCT
both because it is an effective treatment for CLL and
because it is highly immunosuppressive as shown by
others in more high risk diseases. The initial study
yielded a complete response (CR) in 8 of 11 patients,
and donor lymphocyte infusions were able to induce
remissions following transplant, again providing
good evidence of a GVL effect [5]. The Cooperative
German Transplant Study Group evaluated RIC
with fludarabine, busulfan, and antithymocyte globu-
lin in 30 patients with advanced CLL, half of whom
had unrelated donors. They reported 72% overall
survival (OS) at 2 years, with 67% progression-free
survival (PFS) and 15% TRM. Fifty-six percent of
patients developed grades 2-4 acute GVHD, whereas
75% developed cGVHD. Of note, late CRs were
observed up to 2 years after transplant, again providing
evidence of a GVL effect [6]. The 2-year OS among
46 patients with advanced CLLwho received nonmye-
loablative fludarabine and busulfan conditioning at
Dana-Farber Cancer Institute was 54%, with a PFS
of 34%. In this analysis, the primary cause of treatment
failure was relapse, and chemotherapy-refractory
disease at transplant was associated with a 3.2-fold
risk of progression (P 5 .01) and a 4.6-fold risk ofdeath (P 5 .02). Other factors that increased the risk
of relapse were low levels of donor chimerism at day
30, increased number of previous therapies, and
adverse cytogenetics [7]. Five-year follow-up follow-
ing nonmyeloablative transplant has been reported
from a multi-institution protocol led by the Fred
Hutchinson Cancer Research Center. The 5-year
incidences of nonrelapse mortality, OS, and PFS
were 23%, 50%, and 39%, respectively. Of the
patients who survived, 76% were entirely well, where
24% continued to receive immunosuppression for
cGVHD [8]. The CLL3X trial from the German
CLL Study Group was a phase II study that prospec-
tively evaluated the long-term outcome of RIC
HSCT in patients with poor-risk CLL. Ninety
patients received allogeneic transplant following flu-
darabine and cyclophosphamide-based conditioning.
The 4-year nonrelapse mortality, event-free survival
(EFS), andOS were 23%, 42%, and 65%, respectively.
Of the patients with matched related donor monitor-
ing available, 52% were alive and negative at 12
months following transplant, and the 4-year EFS of
this group of patients was 89%. Interestingly, EFS
was similar for all genetic subsets, including patients
with the 17p deletion [9].
Attempts to both improve relapse-free survival
following transplant and to modulate the impact of
GVHD have led investigators to incorporate mono-
clonal antibodies into transplant regimens. Rituximab,
alemtuzumab, and ofatumumab all have single agent
activity in CLL, and rituximab has been shown to
improve OS in previously untreated patients when
added to fludarabine and cyclophosphamide compared
with chemotherapy alone [10]. Immunomanipulation
with rituximab for patients with persistent disease
following nonmyeloablative transplant can induce
responses, and in a series reported by M.D. Anderson,
a survival advantage was observed among patients who
received rituximab as part of their conditioning, in
addition to fludarabine and cyclophosphamide, com-
pared with those who received chemotherapy alone
[11]. The current CALGB CLL transplant study
incorporates rituximab into the conditioning and
includes rituximab maintenance following transplant.
Given alemtuzumab’s ability to deplete T cells, it has
also been incorporated into conditioning, in hopes of
reducing GVHD. Although Delgado et al. [12-14]
report reduced incidence of cGVHD in patients who
received alemtuzumab, the incidence of fungal and
viral infections is increased among those patients,
leading to relatively high TRM, and integration of
alemtuzumab into conditioning has been associated
with inferior PFS, which is consistent with our
institutional observation. The CLL3X study also
found T cell depletion with alemtuzumab to have an
adverse impact on EFS and OS in a multivariate
analysis [9].
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CLL PATIENTS TO RIC HSCT?
Patients with poor-risk features such as del(17p) or
(11q) or immunoglobluin heavy chain variable
(IGHV) unmutated disease have inferior PFS follow-
ing chemotherapy. A case-control study comparing
outcomes of patients who underwent RIC HSCT
with patients who received conventional therapy
demonstrated that the median overall survival was
113 months for HCT patients and 85 months for con-
trols when calculated from the time of diagnosis and
103 and 67 months, respectively, when calculated
from time of first therapy. Both patient groups were
well balanced with respect to cytogenetics, CD38,
and ZAP-70 expression, and IGHV mutational status
[15]. A small retrospective analysis of outcomes among
patients receiving RIC HSCT stratified by prognostic
risk group suggested that RIC HSCT could overcome
the adverse prognosis associated with del(11q) or
del(17p), as well as unmutated IGHV [16]. A study
of 44 patients with del(17p) CLL from the European
Group for Blood and Marrow Transplantation data-
base, 89% of whom received RIC, demonstrated
3-year OS and PFS rates of 44% and 37%, respec-
tively. The cumulative incidence of progressive disease
at 4 years was 34%, and no late relapses occurred in the
9 patients with follow-up longer than 4 years, suggest-
ing a survival plateau in even this high-risk group of
patients. Extensive cGVHD occurred in 53% of
patients [14]. Among a series of 34 patients with unmu-
tated IGHV, the risk of relapse at 5 years was 66%
among patients who received an autologous transplant
versus 17% among patients who received RIC HSCT,
suggesting that allogeneic transplant may overcome
the unfavorable effect of having unmutated disease
[17]. Fit patients with del(17p), those who are refrac-
tory to fludarabine and alemtuzumab, and those who
have a PFS of\24 months after intensive rituximab-
containing therapy should all be considered for RIC
HSCT if remission is achieved [18]. Further refine-
ment of what constitutes a high-risk patient may
broaden the indication for transplant in coming years.
In contrast, development of targeted therapies that
induce durable remission may diminish the number
of CLL patients going forth for transplantation.TARGETED THERAPY IN CML AND
CONTRIBUTION TO CHANGING ROLE
OF HSCT IN THIS DISEASE
Following the introduction of imatinib as a front-
line strategy in CML, the rates of allogeneic HSCT
quickly dropped worldwide, most notably in patients
with chronic phase disease. HSCT maintained a role
in the treatment of patients with high-risk disease, in-
cluding patients in accelerated or blast phase or thosewho had failed imatinib [19]. Although patients in
accelerated and blast phase frequently respond to
TKIs, the response is transient, and HSCT remains
an effective treatment for these patients. Results of
HSCT have been reported in this patient population
and have consistently shown a lack of beneficial or del-
eterious effect of imatinib on transplant, and a recent
analysis by the Center for International Blood and
Marrow Transplant showed that conventional prog-
nostic indicators from the preimatinib era remain the
strongest and that there are no new prognostic indica-
tors for transplant outcomes in the imatinib era [20].
Another population for whom HSCT remains impor-
tant is patients who harbor the T315I mutation, which
confers resistance to all licensed TKIs. An analysis of
64 patients from the European Blood and Marrow
Transplant registry with CML and de novo Ph1 acute
lymphoblastic leukemia and harboring a T315I
mutation demonstrated that survival probabilities
24 months after HSCT were 59%, 67%, 30%, and
25% for chronic phase, accelerated phase, blast phase,
and Ph1 acute lymphoblastic leukemia, respectively. A
myeloablative regimen was used in 60% of the
patients. Multivariate analysis identified blast phase
at transplant and unrelated stem cell donor as unfavor-
able factors [21]. As new, effective agents transition
into the therapy algorithms of CLL, it remains to be
seen if a similar shift toward diminishing need for
allogeneic transplantation will occur.NOVELTARGETED THERAPIES IN CLL
Advances in the biology of CLL have brought
forth a plethora of new targeted agents that ultimately
have great potential to impact the treatment of CLL.
Although there are more than 100 specific agents cur-
rently in clinical trials, only a select few offer both
single agent activity and the potential to induce dura-
ble remissions in high-risk CLL patients making
them potential candidates to delay allogeneic trans-
plantation. These agents are summarized by class in
the sections below.MONOCLONAL ANTIBODIES
Whereas monoclonal antibodies such as rituximab
have greatly improved our ability to cytoreduce and
improve durable remissions in CLL, successes that
will likely build to durable long-term remissions simi-
lar to that seen with imatiniib are unlikely. To date,
improvement in design of CD20 antibodies, including
ofatumumab, which mediates improved complement-
dependent cytotoxicity, and GA101, which promotes
improved direct killing and natural killer (NK)
cell-mediated antibody dependent cellular cytotoxic-
ity, has been the major advance made in antibody
therapeutics. Ofatumumab has been provisionally
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refractory CLL and is under investigation both in
combination with fludarabine/cyclophosphamide ver-
sus fludarabine, cyclophosphamide, and rituximab
(FCR) for younger patients and as amaintenance treat-
ment after chemoimmunotherapy in ongoing random-
ized phase III trials. Ofatumumab induces short
remissions in refractory patients and should be consid-
ered only as a bridge to transition these individuals to
allogeneic transplantation. GA101 is a yet unappro-
ved,Type II glycoengineered humanized CD20mono-
clonal antibody that binds CD20 in a completely
different orientation than rituximab and over a larger
surface area [22]. It initiates nonapoptotic cell death
via an actin-dependent lysosome-mediatedmechanism
that is reliant on cell-to-cell contact [23]. Depletion of
CLL cells in whole blood samples has been demon-
strated, and it may be more potent than rituximab at
similar concentrations [24,25]. The addition of
GA101 to fludarabine, bendamustine, or Bcl-2 family
inhibitors appears to have a synergistic effect in xeno-
graft models [26]. A recently reported phase I study in
13 relapsed/refractory CLL patients demonstrated
that GA101 is relatively well tolerated, with the most
common grade 3-4 toxicity being transient neutrope-
nia in 9 patients. One CRi, 7 partial responses (PRs),
and 3 patients with stable disease were observed. No
clear dose relationship was established [27]. GA101 is
being evaluated in a phase II study as a single-agent
in untreated and relapsed/refractory CLL and in com-
bination with FCR as first-line therapy. A variety of
other therapeutic antibodies are under clinical devel-
opment at this time in CLL but at this point no emer-
gent candidate comes forth that will induce durable
remissions in CLL thereby abrogating eventual need
for transplantation.BCL-2 FAMILYANTAGONISTS
BCL-2 and related family member proteins such as
mcl-1 are overexpressed in CLL and thereby disrupt
apoptosis in this disease. A long history of develop-
ment of Genasense (G3139), a BCL-2 antisense mole-
cule was pursued in CLL with eventual failure in
a randomized phase III study but notably with some
evidence of clinical benefit. Derived from this early
effort was development of small molecule therapeutics
that could interfere with BCL-2 protein binding to
BH3 domain only proteins. The most promising of
these is navitoclax (ABT-263), an orally bioavailable,
BH3 mimetic that inhibits multiple antiapoptotic
Bcl-2 family proteins. In phase I testing, navitoclax
has a favorable pharmacokinetic profile and safety
profile, with dose-limiting toxicities (DLTs) including
tumor lysis syndrome (TLS) and thrombocytopenia
among the CLL cohort. Although thrombocytopenia
was sometimes quite profound, this was shown to bea direct consequence of inhibiting bcl-xl in platelets.
Several patients were able to maintain a .50% reduc-
tion in circulating lymphocytes for over 6 months with
significant reduction in lymph node enlargement [28].
The combination of navitoclax with BR, evaluated in
a phase I study, has thus far been well tolerated, with
no DLTs of thrombocytopenia or neutropenia, and
there was evidence of antitumor activity. Data regard-
ing the combination of navitoclax with FCR is still
being collected [29]. An alternative BCL-2 antagoniz-
ing small molecule (ABT199) that lacks influence on
bcl-xl, which therefore would be predicted to avoid
problematic thrombocytopenia is currently beginning
phase I testing in CLL. Given the durable remission
identified in a subset of ABT-263 patients and en-
hanced ability to combine this class of drugs with other
therapies used in CLL, the likelihood of future contri-
bution of this agent to treatment of advanced CLL is
high.CYCLIN-DEPENDENT KINASES (CDK)
INHIBITORS
One class of drugs that has promise for the treat-
ment of CLL is those that target the cyclin-dependent
kinases (CDK inhibitors). Preclinical investigation of
flavopiridol by our group [30] and others [31,32]
demonstrated that this agent had potent in vitro
activity against CLL cells. Other studies have
demonstrated that cell death promoted by flavopiridol
may be, in part, because of inhibition of CDK9 and
global transcriptional inhibition [33]. Based upon these
studies, several clinical trials investigating a 72 hour
[34], 24 hour [35], and 1 hour [34] infusion of flavopir-
idol were undertaken with minimal evidence of clinical
benefit and with significant toxicity including diarrhea,
cytokine release syndrome, and neutropenia. Likewise,
poor responseswereobservedwithflavopiridol inamul-
titude of solid tumor studies prompting temporary
cessation of development of this compound. Our group
identified differential flavopiridol protein binding
between bovine and human albumin in culture media
and successfully modeled a pharmacokinetic schedule
of administration of flavopiridol that employed
a 30-minute loading dose followed by a 4-hour infusion
of drug to maintain a concentration of 2 mM for 4 to
6 hours [36]. A phase I study using this schedule of ad-
ministration in 52 patients demonstrated the dose
limiting side effect of hyperacute TLS. Other toxicity
observed included biphasic neutropenia and diarrhea.
Of the 52 patients enrolled, 21 patients (40%) achieved
a PR with a median PFS of 12 months [37]. This
phase I study prompted a phase II study of 64 patients,
of which 34 patients (53%) responded [38]. All those
with del(17p13.1) responded irrespective of bulky nodal
status [38]. Amulticenter phase II trial confirmed single
agent flavopiridol activity albeit at a lower frequency
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sults provided support for development of improved
CDK inhibitors inCLL that have improved pharmaco-
logic, protein binding, and off-target effects compared
with flavopiridol.
Dinaciclib is one such selective inhibitor of CDKs
1, 2, 5, and 9 that was identified as having a favorable
therapeutic index in an in vivo cancer screen. In CLL
cells, dinaciclib promotes concentration-dependent
apoptosis independent of IGHV mutational status
and fludarabine-refractoriness, although CLL cells
from patients with del(17p) were more resistant than
cells from patients with normal cytogenetics [39]. In
a phase I study, dinaciclib had an acceptable safety pro-
file, with responses in patients with bulky disease and
in 7 of 15 patients with del(17p). Two cases of tumor
lysis syndrome requiring temporary dialysis were
observed, and an additional cohort is currently ongo-
ing to determine if stepped-up dosing reduces the
incidence of TLS [40]. Notably different from flavo-
piridol is the ability of patients to receive dinaciclib
for an extended period of time without undue side
effects. Both flavopiridol and dinaciclib produce stable
remissions after halting therapy as well, making them
ideal cytoreductive therapies for patients ultimately
going onto RIC HSCT.BCELLRECEPTOR(BCR)KINASE INHIBITORS
Multiple studies have demonstrated the impor-
tance of BCR signaling in the survival of normal and
transformed B cells. This is highlighted in particular
among high risk CLL where ZAP-70 expression is
abundant, which has been shown to indicate enhanced
BCR signaling. Several proximal kinases including syk,
lyn, PI3-kinased, and Bruton’s tyrosine kinase (BTK)
have been targeted by therapeutic small molecule
inhibitors. Early studies with the syk inhibitor demon-
strated clinical activity in CLL. Development of this
agent in CLL, however, has not been pursued for
uncertain reasons.
Phosphatidylinositol-3-kinases (PI3K) integrate
and transmit signals from cell surface markers, includ-
ing the BCR, thereby regulating key cellular functions
such as growth and survival. The PI3Kd isoform is
largely restricted to hematopoietic cells, where it plays
an important role in B cell homeostasis and function
[41]. This offers the opportunity to target PI3K
more selectively, thereby not interfering with insulin
signaling and other off target essential functions asso-
ciated with alternative isoforms. CAL-101 is a highly
selective PI3Kd inhibitor that promotes apoptosis in
B cell lines including CLL [42,43]. CAL-101 reduces
survival signals derived from the microenvironment,
and in stromal cocultures, sensitizes CLL cells toward
bendamustine, fludarabine, and dexamethasone [15].
In a phase I study of patients with relapsed or refrac-tory CLL, CAL-101 proved to be safe, with a .50%
reduction in lymphadenopathy noted in 80% of
patients. Medians for duration of response and PFS
had not been reached as of publication of the abstract
[44]. Notably, toxicity with this regimen has been quite
modest to this point, with DLT in lymphoma being
reversible transaminitis. Studies of CAL-101 in com-
bination with rituximab, ofatumumab, FCR, and BR
are currently ongoing. To this point, the durable
remissions observed in a subset of refractory CLL
patients receiving CAL-101 have mimicked the initial
trials with imatinib in CML where refractory individ-
uals gained significant benefit. The ability to transition
patients off CAL-101 to RIC HSCT at this point is
uncertain, particularly early on in therapy. Further
studies addressing this are warranted.
BTK is a B cell-specific kinase that is located prox-
imally in the BCR pathway and when manipulated,
results in loss of BCR signaling without T or NK
cell defects. PCI-32765, an orally bioavailable BTK
inhibitor, antagonizes this pathway. Like CAL-101,
it also abrogates protective features of the microenvi-
ronment. PCI-32765 was designed as a selective and
irreversible inhibitor of the BTK protein [45]. When
added directly to human whole blood, PCI-32765
inhibits signal transduction from the BCR and blocks
activation of B cells. As with CAL-101, our group
has demonstrated that PCI-32765 promotes apoptosis,
inhibits proliferation of CLL cells and antagonizes
survival signaling derived from the microenvironment
[46]. Data regarding PCI-32765 in CLL has been
reported from 2 clinical studies: a Phase I, first-in-
human study in patients with recurrent B cell lym-
phoma and CLL, and a Phase Ib/II study in patients
with CLL/small lymphocytic leukemia. In the phase
I study, therapy was well tolerated with most adverse
events being less than grade 2. T cell responses were
not altered, and there was no significant depletion of
peripheral blood T or NK cell counts [47]. Of the
78 subjects with CLL/small lymphocytic leukemia
treated on the Phase Ib/II study as of May 2011, only
1 subject came off study because of progressive disease.
Thirty-nine patients were evaluable for response when
last reported, most of whom had at least 1 poor-risk
molecular feature. In patients with lymphadenopathy,
the rate of nodal response (.50% reduction in target
lesions) was 89%. There was a 44% response rate at
a median follow-up of 4 months (39% PR and 5%
CR) per IWCLL/Cheson response criteria, including
responses in patients with del(17p) [48]. Follow-up
studies of the durability of PCI-32765 will remain
quite relevant to the impact on disease control. Studies
of PCI-32765 in combination with ofatumumab, FCR,
and BR are currently ongoing. As with CAL-101, sig-
nificant excitement in the field of CLL exists for this
compound because of continued benefit documented
in very refractory CLL patients. The ability to
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this point is uncertain, particularly early on in therapy.
Further studies addressing this are warranted.IMPACTOF NOVELTHERAPEUTICS ON RIC
HSCT FOR CLL
As the novel therapeutics discussed are in early
phase clinical testing, their impact on and utility in
conjunction with RIC HSCT is completely unknown
at this time. Particularly because patients with high-
risk disease often have inferior PFS following conven-
tional chemotherapy, and as these agents move into
phase II or III testing, it is increasing likely that pa-
tients moving on to transplant will have been exposed
to one or more of these agents. It has been established
that patients with diffuse large B cell lymphoma who
relapse quickly following rituximab-containing ther-
apy have inferior survival following autologous trans-
plant [49]; it is far too early to speculate how these
novel treatments may impact outcomes for patients
with CLL following RIC HSCT. Additionally, for
patients on therapies such as PCI-32765 and CAL-
101 who can remain on treatment until disease pro-
gression or development of unacceptable toxicity, the
timing both of transplant and when to stop the drug
before transplant is not defined. It is also unknown
whether any of these agents may play a role in post-
transplant maintenance or as salvage for patients who
relapse following transplant. Alternative target effects
on NK or dendritic cells may limit applicability for
some new drugs in posttransplant maintenance strate-
gies. Indeed, the field of therapeutics in CLL ismoving
quite quickly and will be influenced by the longer term
follow-up in trials of novel agents, including follow-up
relating to safe integration with RIC HSCT. For now,
our group’s approach has been to follow international
guidelines for application of RIC HSCT, with the
exception of patients gaining a very good early
response to 1 of the BCR kinase inhibitor agents
when alternative novel agents (ie, CDK inhibitor or
BCL-2 antagonist agents) are available for future
cytoreduction should progression occur. Access to
multiple active agents for CLL is necessary for such
an approach, emphasizing the need for continued
development of therapeutics in this disease.ACKNOWLEDGMENTS
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